Clinical trial
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets of Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in Healthy, Adult, Human Subjects Under Fed Condition.
NCT07266779 is registered in ClinicalTrials.gov with Humanis Saglık Anonim Sirketi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets of Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in Healthy, Adult, Human Subjects Under Fed Condition.
- Lead sponsor
- Humanis Saglık Anonim Sirketi
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 22, 2025
- Completion date
- October 11, 2025
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes